Tracking a rare liver disease treatment in real life
NCT ID NCT06850038
Summary
This study follows 30 patients with Alagille syndrome (ALGS), a rare genetic disease that damages the liver, as they take the medication odevixibat (Bylvay) in their daily lives. The main goal is to see how well the drug works and how safe it is over the long term. Researchers will track whether patients need major surgeries like liver transplants and monitor their growth and overall health.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALAGILLE SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Childrens Hospital Los Angeles
RECRUITINGLos Angeles, California, 90027, United States
-
Columbia University
RECRUITINGNew York, New York, 10016, United States
-
Le Bonheur Children's Hospital
RECRUITINGMemphis, Tennessee, 38105, United States
-
NYU Langone - NYU Grossman School of Medicine
RECRUITINGNew York, New York, 10016, United States
-
Proactive El Paso,LLC
RECRUITINGEl Paso, Texas, 79902, United States
-
The Children's Mercy Hospital
RECRUITINGKansas City, Missouri, 64108, United States
-
UCSF Pediatric Gastroenterology
RECRUITINGSan Francisco, California, 94158, United States
-
UT Southwestern Childrens Medical Center
RECRUITINGDallas, Texas, 75235, United States
Conditions
Explore the condition pages connected to this study.